What does the future hold for AI in medical devices?
24 Oct 2022
Digital health, artificial intelligence (AI), machine learning and more — these concepts continue to generate buzz in the medtech world.
Last month, the FDA published guidance on clinical decision support (CDS) software. It helped to clear up what constitutes a medical device and what doesn’t. Early last year, the agency published a predetermined change control plan (PCCP) to help build a regulatory structure for such technology.
These topics and more spurred intriguing commentary on a panel at AdvaMed’s MedTech Conference in Boston today.
The panel featured viewpoints across all angles of the space. Dr. Yuri Maricich, CMO and head of development at Pear Therapeutics, offered thoughts from the developer of digital therapeutics. Brendan O’Leary, acting director of the Digital Health Center of Excellence at the FDA, provided the regulatory vantage point.
Cybil Roehrenbeck, a partner at Hogan Lovells, offered thoughts from the reimbursement side. Cassie Scherer, senior director of digital health policy and regulatory strategy at Medtronic, provided an industry perspective. Diane Johnson, senior director, strategic regulatory, MD&D at Johnson & Johnson, moderated the panel.
Get the full story on our sister site Medical Design & Outsourcing.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.